The US Food and Drug Administration eased up on labeling recommendations but kept a controversial 180-day compliance period in two newly finalized guidance documents aimed at easing the transition out of the COVID-19 public health emergency (PHE), which is set to end in May.
The documents recommend strategies for developing a transition implementation plan, completing a marketing submission, and other key tasks. One applies...